X

Drug Profile

AP 22408

Alternative Names: Signal transduction inhibitor - Takeda/Aventis; Src inhibitor - Takeda/Aventis

Latest Information Update: 07 Sep 2021

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator ARIAD Pharmaceuticals
Class Osteoporosis therapies
Mechanism of Action Src-family kinase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Postmenopausal osteoporosis

Most Recent Events

16 Feb 2017 ARIAD Pharmaceuticals has been acquired by Takeda
23 Apr 2002 Discontinued - Preclinical for Postmenopausal osteoporosis in USA (unspecified route)
04 Dec 2000 A preclinical study has been added to the Musculoskeletal pharmacodynamics section

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com